Pharmacotherapics Advice in Guidelines for COVID-19

Since December 2019 to May 2020, coronavirus disease 2019 (COVID-19) has infected over 6 million people worldwide. Due to its sudden and rapid outbreak, effective treatment for COVID-19 is scarce. Based on national clinical trials of novel treatments, China, Italy, Germany, and other countries and o...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2020-06, Vol.11, p.950-950
Main Authors: Chen, Zhang-Ren, Zhou, Ying, Liu, Jin, Peng, Hong-Wei, Zhou, Jian, Zhong, Hai-Li, Liu, Li-Li, Lai, Ming-Fang, Wei, Xiao-Hua, Wen, Jin-Hua
Format: Article
Language:English
Subjects:
COVID-19
guideline
Pharmacology
pharmacotherapy
pneumonia
SARS-CoV-2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Since December 2019 to May 2020, coronavirus disease 2019 (COVID-19) has infected over 6 million people worldwide. Due to its sudden and rapid outbreak, effective treatment for COVID-19 is scarce. Based on national clinical trials of novel treatments, China, Italy, Germany, and other countries and organizations have published multiple guidelines for COVID-19 and advised many medicines, such as chloroquine and tocilizumab. In this paper, we summarize the pharmacotherapy for COVID-19 according to those guidelines, highlight updates of the pharmacotherapy guidelines, and review the efficacy and safety of the indicated anti-COVID-19 drugs.
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2020.00950